<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">768698</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2021.768698</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Recent Progresses in NIR-I/II Fluorescence Imaging for Surgical Navigation</article-title>
<alt-title alt-title-type="left-running-head">Li et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Fluorescence Imaging for Surgical Navigation</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Songjiao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheng</surname>
<given-names>Dan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>He</surname>
<given-names>Longwei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1462890/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Lin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/472552/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Cancer Research Institute, Department of Pharmacy and Pharmacology, The First Affiliated Hospital, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medical School, University of South China, <addr-line>Hengyang</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, <addr-line>Hengyang</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, <addr-line>Changsha</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1130949/overview">Yao Sun</ext-link>, Central China Normal University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/723554/overview">Zuhai Lei</ext-link>, Fudan University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1465669/overview">Chunyan Li</ext-link>, Suzhou Institute of Nano-Tech and Nano-Bionics (CAS), China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Longwei He, <email>helongwei0110@163.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Nanobiotechnology, a section of the journal Frontiers in Bioengineering and Biotechnology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>768698</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>09</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Li, Cheng, He and Yuan.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Li, Cheng, He and Yuan</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Cancer is still one of the main causes of morbidity and death rate around the world, although diagnostic and therapeutic technologies are used to advance human disease treatment. Currently, surgical resection of solid tumors is the most effective and a prior remedial measure to treat cancer. Although medical treatment, technology, and science have advanced significantly, it is challenging to completely treat this lethal disease. Near-infrared (NIR) fluorescence, including the first near-infrared region (NIR-I, 650&#x2013;900&#xa0;nm) and the second near-infrared region (NIR-II, 1,000&#x2013;1,700&#xa0;nm), plays an important role in image-guided cancer surgeries due to its inherent advantages, such as great tissue penetration, minimal tissue absorption and emission light scattering, and low autofluorescence. By virtue of its high precision in identifying tumor tissue margins, there are growing number of NIR fluorescence-guided surgeries for various living animal models as well as patients in clinical therapy. Herein, this review introduces the basic construction and operation principles of fluorescence molecular imaging technology, and the representative application of NIR-I/II image-guided surgery in biomedical research studies are summarized. Ultimately, we discuss the present challenges and future perspectives in the field of fluorescence imaging for surgical navigation and also put forward our opinions on how to improve the efficiency of the surgical treatment.</p>
</abstract>
<kwd-group>
<kwd>surgical navigation</kwd>
<kwd>NIR-I</kwd>
<kwd>NIR-II</kwd>
<kwd>tumor</kwd>
<kwd>fluorescence imaging</kwd>
<kwd>image-guided cancer surgeries</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>As an extremely aggressive disease for human health, cancer is still one of the most fatal diseases and the main cause of death across the world (<xref ref-type="bibr" rid="B48">Torre et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B49">Torre et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B7">de Groot et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B15">Feng et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B43">Rawla, 2019</xref>). On the basis of the recent investigation conducted by the World Health Organization (WHO), there was an increase of about 18 million cases of cancer globally, including almost 10 million patients dying from cancer in 2018 (<xref ref-type="bibr" rid="B2">Bray et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B5">Curry et&#x20;al., 2019</xref>). Although some tumor surgeries have been advanced methodologically in the past few decades, there is no significant overall growth in the cure (<xref ref-type="bibr" rid="B10">Esserman et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B25">Kamzan and Ng, 2021</xref>). As a dynamic process, cancer progression experiences genetic mutation or excision, elementary tumor generation, vascularization, aggression, and secondary tumor generation (<xref ref-type="bibr" rid="B17">Hanahan and Weinberg, 2011</xref>; <xref ref-type="bibr" rid="B13">Faubert et&#x20;al., 2020</xref>). Thus, through precise distinction of tumor areas and complete surgical resection of tumor tissues with negative margins, the prognosis of the disease could be improved while decreasing the rate of recurrence.</p>
<p>For satisfying the abovementioned requirements, tumor diagnosis and therapeutic evaluation have been developed and employed in different medical imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), ultrasonic imaging (USI), and single photon emission computed tomography (SPECT) (<xref ref-type="bibr" rid="B39">Owens et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B14">Feher and Sinusas, 2017</xref>; <xref ref-type="bibr" rid="B62">Yun and Kwok, 2017</xref>; <xref ref-type="bibr" rid="B18">He et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B56">Xia et&#x20;al., 2019</xref>). Preoperative diagnosis can apply those imaging approaches, whereas fluorescence image-guided surgery helps surgeons to accurately identify the cancerous tissue by using fluorescence approaches for intraoperative imaging (<xref ref-type="bibr" rid="B36">Nagaya et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B20">Hu et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B35">Mangeolle et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B51">Wang C. et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B19">Hernot et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B38">Olson et&#x20;al., 2019</xref>). Excitation/emission wavelengths within the NIR-I or NIR-II scopes have been adopted to develop a lot of fluorescence image-guided surgery dye platforms, including small-molecule fluorogenic chromophores (such as indocyanine green (ICG), cyanine 7 (Cy7), hemicyanine, dicyanomethylene pyran (DCM), and phenothiazine (PTZ) derivatives) and fluorogenic nanomaterial (such as aggregation-induced emission (AIE) dots, amphipathic polymer, lanthanide nanoparticle, Ag<sub>2</sub>S nanochain, and DNA-functionalized nanoparticle). Small-molecule fluorogenic probes usually perform quick feedback, have high sensitivity and excellent selectivity, and easy adjustment of optical properties through structural modification; however, their response emission and imaging applications might suffer the intrinsic disadvantages of organic compounds, such as poor water solubility generated by large &#x3c0;-conjugated structures, low quantum yield generated by non-rigid structures, fake signal induced by unstable chemical structures and environment-vulnerable emission, self-quenching induced by small stokes shift, and so on. In comparison, the NIR nanoprobes based on fluorogenic nanomaterials or small-molecule chromophores modified by nanoparticles tend to own high stability, good water dispersibility, good biocompatibility, and high fluorescence brightness, which leads to the capability of long-term <italic>in vivo</italic> imaging. Meanwhile, there are some disadvantages to the fluorescent nanoparticles, for example, it takes long time to penetrate the cell member for the large-size particles, and nanoparticles are metabolized slowly <italic>in vivo</italic> and substantial cumulation in the body resulting in organ injury.</p>
<p>Fluorescence imaging in the first near-infrared region (NIR-I, 650&#x2013;900&#xa0;nm) has received widespread attention in biomedical research studies because of its quick feedback, high sensitivity, harmless radiation, and lower cost (<xref ref-type="bibr" rid="B33">Liu et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B24">Ji et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B23">Jackson et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B58">Yan et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B61">Yu et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B64">Zeng et&#x20;al., 2021</xref>). For example, NIR-I fluorophores utilizing reasonable design strategies were extensively used for biomedical usage including precise real-time sentinel lymph nodes/tumor description and intraoperative image-guided surgical resection of sentinel lymph nodes/tumor tissues (<xref ref-type="bibr" rid="B28">Li et&#x20;al., 2021</xref>). Relatively deep penetration and high imaging quality can be achieved with fluorophores with emissions in the NIR-I region by comparing with visible wavelengths. In addition, recent research studies indicate that high-quality fluorescence images and a signal-to-background ratio (SBR) can be induced by fluorescence imaging at the second near-infrared region (NIR-II, 1,000&#x2013;1700&#xa0;nm) than at the NIR-I region (<xref ref-type="bibr" rid="B22">Huang and Pu, 2020</xref>; <xref ref-type="bibr" rid="B42">Qian et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B66">Zhang et&#x20;al., 2020</xref>). The applications of this innovative NIR-II region in biomedical imaging have significantly improved the temporal and spatial resolution and penetration depth because of negligible tissue absorption, weakened scattering, and minimum autofluorescence (<xref ref-type="bibr" rid="B9">Ding et&#x20;al., 2018b</xref>; <xref ref-type="bibr" rid="B50">Wan et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B6">Dai et&#x20;al., 2021</xref>). As a rapidly developing technology, near-infrared fluorescence-guided surgery helps surgeons in determining the tumor margins of some cancer types and the lesions of other common diseases with great accuracy (<xref ref-type="scheme" rid="sch1">Scheme 1</xref>) (<xref ref-type="bibr" rid="B27">Li et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B67">Zhu et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B55">Wu and Zhang, 2020</xref>; <xref ref-type="bibr" rid="B57">Xu et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B60">Yang et&#x20;al., 2021</xref>).</p>
<fig id="sch1" position="float">
<label>SCHEME 1</label>
<caption>
<p>Illustrative representation of NIR-I/II fluorescence imaging technology and its applications in guided surgery.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g013.tif"/>
</fig>
<p>Herein, this review summed up the recent progress in developing fluorescence imaging-guided surgery by two kinds of NIR imaging (NIR-I and NIR-II fluorescence). We will briefly cover background and design considerations focusing on representative examples applied in fluorescence image-guided surgery. The performance comparison of fluorescent probes used in related highlight researches is summarized in <xref ref-type="table" rid="T1">Table&#x20;1</xref>. Finally, the discussion on the current challenges and future perspectives in the field of fluorescence imaging-guided surgical navigation is showed in the final section, and the opinions on how to improve the efficiency of the surgical treatment are also put forward by&#x20;us.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Summary performance comparison of fluorescence image-guided surgery dye platforms.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Probe name</th>
<th align="center">Ex/Em (nm/nm)</th>
<th align="center">Imaging modality</th>
<th align="center">Analytes</th>
<th align="center">Surgical application</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">BL-760</td>
<td align="char" char=".">760/783</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Hepatobiliary surgery</td>
<td align="left">
<xref ref-type="bibr" rid="B34">Luciano et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">TER-SA</td>
<td align="char" char=".">760/780</td>
<td align="left">FL</td>
<td align="left">&#x3b1;<sub>v</sub>&#x3b2;<sub>3</sub> integrin</td>
<td align="left">Renal carcinoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B1">An et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">TPA-TQ3 NPs</td>
<td align="char" char=".">600/800</td>
<td align="left">FL/PA</td>
<td align="left">none</td>
<td align="left">Breast tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B16">Gao et&#x20;al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">VGT-309</td>
<td align="char" char=".">750/773</td>
<td align="left">FL</td>
<td align="left">Cathepsins</td>
<td align="left">Breast tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B46">Suurs et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">P-Cy-FF-Gd</td>
<td align="char" char=".">688/710</td>
<td align="left">FL/MR</td>
<td align="left">Alkaline phosphatase</td>
<td align="left">Liver tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B59">Yan et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">BH-NO2@BSA</td>
<td align="char" char=".">680/791</td>
<td align="left">FL/PA</td>
<td align="left">Nitroreductase</td>
<td align="left">Liver tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B65">Zeng et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">YH-APN</td>
<td align="char" char=".">445/650</td>
<td align="left">FL</td>
<td align="left">Aminopeptidase N</td>
<td align="left">Liver tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B29">Li et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">IRDye800CW-SAHA</td>
<td align="char" char=".">760/801</td>
<td align="left">FL</td>
<td align="left">Histone deacetylase</td>
<td align="left">Liver tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B47">Tang et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">TPE-Ph-DCM</td>
<td align="char" char=".">465/671</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Peritoneal tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B37">Ni et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">DSPE-PEG-AIE dots</td>
<td align="char" char=".">445/650</td>
<td align="left">FL/BL</td>
<td align="left">None</td>
<td align="left">Peritoneal tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B4">Chen et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">PTZ-BT-TPA</td>
<td align="char" char=".">480/650</td>
<td align="left">FL/BL</td>
<td align="left">None</td>
<td align="left">Peritoneal tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B40">Qi et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">OTPA-TQ3 NPs</td>
<td align="char" char=".">650/900</td>
<td align="left">FL/RL</td>
<td align="left">None</td>
<td align="left">Osteosarcoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B41">Qi et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">H3-PEG2k</td>
<td align="char" char=".">760/1,023</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Mammary carcinoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B63">Zeng et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">BPN-BBTD@F127</td>
<td align="char" char=".">710/930</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Bowel resection</td>
<td align="left">
<xref ref-type="bibr" rid="B12">Fan et&#x20;al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="left">ICG</td>
<td align="char" char=".">808/980</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Liver tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B21">Hu et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">CH1055-4Glu-AE105</td>
<td align="char" char=".">750/1,055</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Glioblastoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B26">Kurbegovic et&#x20;al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">DCNPs</td>
<td align="char" char=".">808/1,060</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Lymph node resection</td>
<td align="left">
<xref ref-type="bibr" rid="B52">Wang et&#x20;al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">IDSe-IC2F NPs</td>
<td align="char" char=".">793/1,010</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Lymph node resection</td>
<td align="left">
<xref ref-type="bibr" rid="B11">Fan et&#x20;al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="left">PDFT1032</td>
<td align="char" char=".">808/1,032</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Osteosarcoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B44">Shou et&#x20;al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">RENPs@Lips</td>
<td align="char" char=".">808/1,064</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Osteosarcoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B27">Li et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">RBCp</td>
<td align="char" char=".">980/835</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Osteosarcoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B53">Wang et&#x20;al. (2019b)</xref>
</td>
</tr>
<tr>
<td align="left">SCH4</td>
<td align="char" char=".">739/1,050</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Osteosarcoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B8">Ding et&#x20;al. (2018a)</xref>
</td>
</tr>
<tr>
<td align="left">
<sup>68</sup>Ga-CHS2</td>
<td align="char" char=".">808/1,055</td>
<td align="left">FL/PET</td>
<td align="left">None</td>
<td align="left">Osteosarcoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B45">Sun et&#x20;al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">IR-BEMC6P</td>
<td align="char" char=".">808/1,025</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Osteosarcoma resection</td>
<td align="left">
<xref ref-type="bibr" rid="B31">Liu et&#x20;al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">2TT-m, oC6B NPs</td>
<td align="char" char=".">777/1,059</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Peritoneal tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B31">Liu et&#x20;al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">pNIR4-PAE NPs</td>
<td align="char" char=".">750/1,040</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Peritoneal tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B54">Wen et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">APP-Ag<sub>2</sub>S-RGD</td>
<td align="char" char=".">808/1,200</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Peritoneal tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B30">Ling et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">FEAD1</td>
<td align="char" char=".">1,094/1,200</td>
<td align="left">FL</td>
<td align="left">None</td>
<td align="left">Peritoneal tumor resection</td>
<td align="left">
<xref ref-type="bibr" rid="B30">Ling et&#x20;al. (2020)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2">
<title>NIR-I Fluorescence Imaging Technology for Guided Surgery</title>
<p>There is a wide application prospect of fluorescence imaging technologies in the biomedical field for the monitoring of physiological and pathological courses at the molecular and cellular levels by right of its intrinsic merits, including high spatiotemporal resolution, favorable sensitivity, and biocompatibility. Particularly, NIR-I emission (650&#x2013;900&#xa0;nm) instead of UV or visible fluorescence molecules is interested in applying <italic>in vivo</italic> fluorescence imaging because of its ability to greatly eliminate autofluorescence, decrease photon scattering, and enhance in-depth tissue penetration (<xref ref-type="bibr" rid="B33">Liu et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B24">Ji et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B23">Jackson et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B58">Yan et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B64">Zeng et&#x20;al., 2021</xref>). As stated earlier, <italic>in vivo</italic> fluorescence imaging utilizing NIR light with longer wavelengths (650&#x2013;900&#xa0;nm), rather than ultraviolet or visible light, is effective in minimizing interference from biological optical absorbers. The NIR-I fluorescent probe is able to analyze the selective visualization of the tumor location and metastatic foci satisfactorily, which has attracted widespread attention for image-guided surgeries. This section focuses on the current representative examples of NIR-I fluorescence imaging technology on surgical navigation.</p>
<sec id="s2-1">
<title>Hepatobiliary Surgery</title>
<p>Cha et&#x20;al. reported a biliary tract&#x2013;targeting NIR fluorescent chromophore BL (bile label)-760 (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 760&#xa0;nm/783&#xa0;nm) (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>) (<xref ref-type="bibr" rid="B34">Luciano et&#x20;al., 2019</xref>). Different from ICG, BL-760 is superior with regard to its capacities, such as lower function doses (90&#xa0;&#x3bc;g/kg), much less duration to biliary excretion, and a higher target-to-background ratio (TBR, 4.48 at 10&#xa0;min) of the cystic duct relative to the liver parenchyma. For demonstrating its efficacy in hepatectomy, authors conducted the hepatic resection surgery of the left lobectomy in pigs. During the surgery, the intrahepatic ducts were clearly highlighted, and bile leakage was easily detected. After carefully dissecting the liver hilum, Calot&#x2019;s triangle was exposed and visualized successfully (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>). All results validated that BL-760 has highly promising properties for intraoperative navigation during hepatobiliary surgery.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>
<bold>(A)</bold> Chemical structures of the fluorescent dye BL (bile label)-760. <bold>(B)</bold> Dissection on the liver hilum (left) and liver resection surgery (right). Adapted with permission from <xref ref-type="bibr" rid="B34">Luciano et&#x20;al. (2019)</xref>. <bold>(C)</bold> Schematic illustration of the molecular design. <bold>(D)</bold> Typical macroscopic figures of the orthotopic 786-O xenograft mice sample (left). Related NIR fluorescence figures of the orthotopic 786-O xenograft mice sample after intravenously governing the TER measure (middle). Arbitrary biopsy (<italic>n</italic>&#x20;&#x3d; 5) at the margin (right). Adapted with permissions from <xref ref-type="bibr" rid="B1">An et&#x20;al. (2020)</xref>. </p>
</caption>
<graphic xlink:href="fbioe-09-768698-g001.tif"/>
</fig>
</sec>
<sec id="s2-2">
<title>Renal Carcinoma Resection</title>
<p>To develop fluorescent molecular tools for image-guided surgeries, Wang et&#x20;al. reported an NIR probe for imaging renal cell carcinoma based on peptides (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 760&#xa0;nm/780&#xa0;nm) (<xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>) (<xref ref-type="bibr" rid="B1">An et&#x20;al., 2020</xref>). On the basis of the design given by the authors, the peptide specifically binds to integrins overexpressed on the cancer cells, and the peptide required to release the self-assembled peptide enclosed with the cyanine dye was cleaved by MMP2/9 enzyme overexpressed cancer cells to generate fluorescent nanoparticles on the surface of the cells. After determining the <italic>in-situ</italic> enzyme-caused self-assembly of the NIR peptide probes on cancer cells, the probes on tumor lesions in a murine model were tested by the authors. Whether the NIR peptide probe could detect tumor precisely in orthotopic RCC models was further investigated by the authors. By virtue of the NIR imaging system, the clear visualization of the whole tumor margins could be performed, and a satellite lesion (&#x3c;1&#xa0;mm) could be detected (<xref ref-type="fig" rid="F1">Figure&#x20;1D</xref>). The probe, playing an excretion-reducing role in the kidney, enabled the identification of little lesions for complete tumor resection and greatly decreased the postoperative recurrence of the tumor by comparison with conventional surgeries. Besides, the tumor-specific excretion-retarded (TER) role was verified by applying a model of <italic>ex vivo</italic> kidney perfusion.</p>
</sec>
<sec id="s2-3">
<title>Breast Tumor Resection</title>
<p>Ding et&#x20;al. reported a superb probe (TPA-TQ3 NPs, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 600&#xa0;nm/800&#xa0;nm) employing a donor&#x2013;acceptor (D-A) construction strategy in which triphenylamine (TPA) and thiadiazoloquinoxaline (TQ) were selected as the donor and acceptor moieties, respectively (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>) (<xref ref-type="bibr" rid="B16">Gao et&#x20;al., 2021</xref>). The mixture with heavy intramolecular action showed an enlarged photoacoustic (PA) signal by enhancing the thermal-to-acoustic shift, and the fluorescence emission intensity also was enhanced because of an aggregation-caused emission (AIE) signature. With high sensitivity and equipment flexibility of fluorescence imaging, it becomes an optimal choice for quick intraoperation imaging, which has also been applied clinically. As shown in <xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>, tiny tumor tissues were detected unambiguously in real-time due to intraoperative NIR fluorescence imaging. It was observed that the fluorescence signal was on a good basis of the bioluminescence from the tumor cells expressed by luciferase, which determined that the fluorescence-marked regions were indeed tumor tissues. With the synchronously large PA signal and fluorescence brightness of TPA-TQ3 NPs, image-guided surgery was precisely carried out. This research study emphasizes a novel design guide of intramolecular motion, amplifying the PA&#x20;role.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<bold>(A)</bold> Chemical structure of TPA-TQ3. <bold>(B)</bold> Typical pre-, intra- and post-surgical fluorescence/bioluminescence images of orthotopic 4T1 breast tumor. Adapted with content from <xref ref-type="bibr" rid="B16">Gao et&#x20;al. (2021)</xref>. <bold>(C)</bold> Chemical structure of VGT-309. <bold>(D)</bold> White light and fluorescent images of the surgical area before and after tumor removal. Adapted with permission from <xref ref-type="bibr" rid="B46">Suurs et&#x20;al. (2020)</xref>.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g002.tif"/>
</fig>
<p>In another study, Dam et&#x20;al. formulated a cathepsin-targeting fluorescent cysteine cathepsin probe, VGT-309 (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 750&#xa0;nm/773&#xa0;nm) (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>) (<xref ref-type="bibr" rid="B46">Suurs et&#x20;al., 2020</xref>). The authors investigated the potential applications of cathepsin-directed imaging with VGT-309 for surgically resecting the 4T1 tumor. <xref ref-type="fig" rid="F2">Figure&#x20;2D</xref> shows the image-guided surgeries of mice after administering the probe injection. The fluorescent signal well-delineated the tumor before removal. After tumor removal, the fluorescent signal in the tumor bed declined greatly. Cathepsins are overexpressed in breast cancer, and this outcome supports the potential practical applied value of VGT-309 for fluorescence imaging-guided surgeries among patients suffering from breast cancer.</p>
</sec>
<sec id="s2-4">
<title>Liver Tumor Resection</title>
<p>Ye et&#x20;al. developed an NIR fluorescence/MRI dual-modal probe for <italic>in vivo</italic> fluorescence imaging (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>) (<xref ref-type="bibr" rid="B59">Yan et&#x20;al., 2019</xref>). The small-molecule probe (P-Cy-FF-Gd) includes an alkaline phosphatase activatable NIR fluorophore (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 688&#xa0;nm/710&#xa0;nm), a self-gathering dipeptide, and a magnetic resonance (MR) contrasting agency. The authors declared that the overexpression of endogenous ALP on cancer cell membranes and the elimination of the phosphate group on the fluorophore (Cy) could lead to the self-assembly of the dephosphorylated probe (CyFF-Gd) into nanoparticles, resulting in simultaneous fluorescence enhancement &#x3e;70-fold and about 2.3-fold r1 increase in relaxivity. P-CyFF-Gd was employed for mapping orthotopic liver tumor margins in intraoperative mice and dissecting the orthotopic HepG2/Luc tumor in intraoperative mice under the guidance of fluorescence imaging by the direct spraying of P-CyFF-Gd on the liver. Thirty&#xa0;minutes later, strong fluorescence, precisely delineating tumor margins in the liver, was produced and could effectively and surgically resect the tumor tissue (<xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>
<bold>(A)</bold> Chemical construction of P-CyFF-Gd and suggested alkaline phosphatase&#x2013;adjusted fluorogenic reaction and <italic>in situ</italic> self-gathering of P-CyFF-Gd into NPs. <bold>(B)</bold> Fluorescence-guided surgery of the orthotopic liver tumor. Adapted with consent from <xref ref-type="bibr" rid="B59">Yan et&#x20;al. (2019)</xref>. <bold>(C)</bold> Schematic explanation of production of the nanocomposite probe BH-NO<sub>2</sub>@BSA and its response to nitroreductase. <bold>(D)</bold> Image-guided tumor resection surgery using the nanocomposite probe. Adapted with consent from <xref ref-type="bibr" rid="B65">Zeng et&#x20;al. (2020)</xref>. (E) Schematic explanation indicating the course of activating YH-APN for APN among cancer cells. <bold>(F)</bold> <italic>In vivo</italic> imaging of mice bearing tumor and image-guided surgeries realized by the spray of YH-APN. Adapted with consent from <xref ref-type="bibr" rid="B29">Li et&#x20;al. (2020)</xref>. <bold>(G)</bold> Chemical structure of IRDye800CW-SAHA. <bold>(H)</bold> H1: Intraoperative NIR fluorescence imaging of the liver tumor after injecting IRDye800CW-SAHA. H2: immunohistochemical staining for histone deacetylase 6 and H&#x26;E staining among tumor tissues (<xref ref-type="bibr" rid="B47">Tang et&#x20;al., 2020</xref>).</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g003.tif"/>
</fig>
<p>It is important to exert more focus on digging the approaches with the precise image of the tumor, which is crucial for resecting and treating the tumor. An activatable fluorescent nanoprobe BH-NO<sub>2</sub>@BSA (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 680&#xa0;nm/791&#xa0;nm) including bovine serum albumin (BSA) and a molecular probe (BH-NO<sub>2</sub>) was synthesized by Wu et&#x20;al., which could particularly answer nitroreductase (NTR) in liver tumor cells and generate stressed NIR and multispectral optoacoustic tomography (MSOT) signals (<xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>) (<xref ref-type="bibr" rid="B65">Zeng et&#x20;al., 2020</xref>). Applying this nanoprobe, the locations of orthotopic liver tumors were accurately determined by 3D MSOT images at the preoperative stage, and after that the tumors were completely removed under the intraoperative guidance of NIR-I and -II bioimaging (<xref ref-type="fig" rid="F3">Figure&#x20;3D</xref>).</p>
<p>Most recently, Peng et&#x20;al. disclosed a DCM-based fluorescent activatable probe by aminopeptidase N (APN) for image-guided surgeries through <italic>in situ</italic> spraying (<xref ref-type="bibr" rid="B29">Li et&#x20;al., 2020</xref>). Guided by the fluorescence signal after probe activation, the probe YH-APN (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 445&#xa0;nm/650&#xa0;nm) (<xref ref-type="fig" rid="F3">Figure&#x20;3E</xref>) was sprayed to precisely eliminate the tumor. YH-APN is capable of specially lighting up the <italic>in situ</italic> solid tumor in real-time with ratio values of 13.86, 4.42, 6.25, and 4.99 for subcutaneous transplantation tumor, hepatic metastasis, and splenic metastasis to normal tissue, respectively, <italic>via in&#x20;situ</italic> spraying techniques (<xref ref-type="fig" rid="F3">Figure&#x20;3F</xref>). More importantly, YH-APN is able to trail metastasis tumor tissues with a diameter of less than one&#xa0;mm, and the fluorescent tissues from the mouse could be precisely removed with a scalpel, explaining the potential of YH-APN to be used as a fluorescent contrast agent in surgical resection. The application of enzyme-activatable fluorescent probes might be promoted by such research studies to diagnose the tumor and surgeries under the guidance of images.</p>
<p>Tian et&#x20;al. developed a new histone deacetylase&#x2013;directed near-infrared probe IRDye800CW-SAHA (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 760&#xa0;nm/801&#xa0;nm) for hepatocellular carcinoma imaging and fluorescence image-guided surgery (<xref ref-type="fig" rid="F3">Figure&#x20;3G</xref>) (<xref ref-type="bibr" rid="B47">Tang et&#x20;al., 2020</xref>). Encouraged by these <italic>in vivo</italic> imaging outcomes, the authors induced the intraoperative liver tumor imaging and image-guided resection with IRDye800CW-SAHA. As displayed in <xref ref-type="fig" rid="F3">Figure&#x20;3H1</xref>, great comparison between the tumor region and normal ambient tissue after the administration of the probe was showed by the intraoperative NIR fluorescence imaging, and the clear visualization and ready distinction of the liver tumor from the nearby normal tissues were drawn. After surgical resection of the fluorescence-positive tumor tissues, the tumor was kept ahead for the histologic (H&#x26;E staining) exploration (<xref ref-type="fig" rid="F3">Figure&#x20;3H2</xref>), which determined that the resected tissues were tumor-directed tissues, indicating the smooth execution of hepatocellular carcinoma resection by fluorescence navigation. The authors validated HDAC6 expression in hepatocellular carcinoma tumor tissues by performing immunohistochemical analysis, which exerted a significant effect on hepatocellular carcinoma pathogenesis and progression.</p>
</sec>
<sec id="s2-5">
<title>Peritoneal Tumor Resection</title>
<p>Ding et&#x20;al. reported an NIR afterglow luminescent nanoparticle with aggregation-caused emission (AIE) features (known as AGL AIE dots) (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>) (<xref ref-type="bibr" rid="B37">Ni et&#x20;al., 2019</xref>). The precursor of phenoxy-dioxetane (mixture 3) and an AIE photosensitizer (TPE-Ph-DCM, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 465&#xa0;nm/671&#xa0;nm) was encapsulated by applying the amphiphilic copolymer lipid&#x2014;PEG 2000 to generate nanoparticles (AGL AIE dots) (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>). Ultralong NIR afterglow luminescence imaging achieved low afterglow background noise and ultrahigh tumor-to-liver/spleen signal proportion (34.2/29.1), enabling AGL AIE dots to perform outstandingly in accurate image-guided cancer surgeries in living mice. According to <xref ref-type="fig" rid="F4">Figure&#x20;4C</xref>, the microtumors in peritoneal carcinomatosis&#x2013;bearing mice could be clearly differentiated by NIR afterglow imaging of the AGL AIE dot, but fluorescence imaging (tumor-to-liver/spleen signal ratio, 0.35/0.61) failed to do it. Besides, guided by afterglow imaging, a surgical operation could remove all the tiny tumor nodules. The results indicated that the afterglow luminescent nanoparticle is able to break the main barrier of signal disturbance in the liver for nanoprobes applied in practically and surgically treating the peritoneal metastatic&#x20;tumor.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>
<bold>(A)</bold> Chemical structures of compounds 3, 4, 10, and TPE-Ph-DCM. <bold>(B)</bold> Schematic explanation of the mechanism for enlarged NIR afterglow luminescence of the AGL AIE dots. <bold>(C)</bold> Representative NIR fluorescence and afterglow imaging of the peritoneal carcinomatosis&#x2013;bearing mice. Adapted with consent from <xref ref-type="bibr" rid="B37">Ni et&#x20;al. (2019)</xref>. <bold>(D)</bold> Chemical constructions of the AIEgens. <bold>(E)</bold> S-AIE dots and DSPE-PEG-AIE dots and chemical construction of CC5A-12C. <bold>(F)</bold> Fluorescence imaging and bioluminescence imaging of the intraperitoneal tumor nodules from mice after intravenously injecting 1-loaded S-AIE dots for 24&#xa0;h. Adapted with consent from <xref ref-type="bibr" rid="B4">Chen et&#x20;al. (2020)</xref>. <bold>(G)</bold> Chemical structure of PTZ-BT-TPA. <bold>(H)</bold> Schematic illustration preparing AIE NPs with a nanoprecipitation approach. <bold>(I)</bold> Representative fluorescence and bioluminescence imaging of the peritoneal carcinomatosis&#x2013;bearing mice. Adapted with permission from <xref ref-type="bibr" rid="B40">Qi et&#x20;al. (2020)</xref>.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g004.tif"/>
</fig>
<p>To achieve the final objective of accurate image-guided cancer surgery, Ding et&#x20;al. proposed an alternative category of fluorescent probes with ultrahigh brightness by using the AIE nature and host&#x2013;guest complexes between calix[5]arene and AIEgen (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 445 nm/650&#xa0;nm) for ultrasensitive fluorescence image-guided cancer surgery therapy (<xref ref-type="fig" rid="F4">Figures 4D,E</xref>) (<xref ref-type="bibr" rid="B4">Chen et&#x20;al., 2020</xref>). The restriction of the intramolecular motion of AIEgens contributes to negligible cytotoxic reactive oxygen species production. According to <italic>in vivo</italic> research studies with a peritoneal carcinomatosis&#x2013;bearing murine model, the supramolecular AIE dot has the capacity to effectively accumulate into and illuminate intraperitoneal tumor nodules, and the SBR value for dot-treated mice has been calculated as 48.5&#x20;&#xb1; 5.6. Under the guidance of superb NIR fluorescence imaging, the tumor removal surgery was effectively performed (<xref ref-type="fig" rid="F4">Figure&#x20;4F</xref>).</p>
<p>Tang et&#x20;al. reported a type of dragonfly-shaped NIR AIEgen (PTZ-BT-TPA, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 480&#xa0;nm/650&#xa0;nm) with a great absorption coefficient and high fluorescence quantum yield for biomedical imaging and surgical navigation (<xref ref-type="fig" rid="F4">Figure&#x20;4G</xref>) (<xref ref-type="bibr" rid="B40">Qi et&#x20;al., 2020</xref>). The assembly of hydrophobic AIEgens is performed in the key, and the amphipathic polymer 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (DSPE-PEG<sub>2000</sub>) produces the shell (<xref ref-type="fig" rid="F4">Figure&#x20;4H</xref>). According to <xref ref-type="fig" rid="F4">Figure&#x20;4I</xref>, while blending the surgeon with the fluorescence signal, his experience excised many tumor nodules with a diameter &#x3e;1&#xa0;mm. Nevertheless, the fluorescence signal was observed after the unguided surgery. Then, guided by NIR fluorescence, the surgeon implemented the second surgery to eliminate the remaining tumor, particularly the small tumor nodules which were not harvested fully with lack of guidance. Due to great brightness of AIE NPs, many more tiny nodules (diameter &#x3c;1&#xa0;mm) than the un-guided group, were caught by the fluorescence image-guided surgery. Well-overlapping of fluorescence and bioluminescence from the resected nodules was found, verifying the greatly increased surgery precision with the help of NIR fluorescence. To be collective, according to these outcomes, the greatly bright AIE NPs can be a potent probe for accurate image-guided cancer surgeries.</p>
</sec>
<sec id="s2-6">
<title>Osteosarcoma Resection</title>
<p>Tang et&#x20;al. disclosed a type of one-for-all organic agent, in which the molecular structure and intramolecular motion can be tuned to synchronously boost the fluorescence, photoacoustic, and Raman nature, for triple modality image-guided accurate cancer surgeries (<xref ref-type="fig" rid="F5">Figure&#x20;5A</xref>) (<xref ref-type="bibr" rid="B41">Qi et&#x20;al., 2019</xref>). Utilizing large sensitivity of fluorescence imaging, excellent spatial resolution, and penetration depth of the PA technique, preoperative tumor investigation and the guidance of the surgical scheme was induced by the intravenously administrated OTPA-TQ3 NPs (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 650&#xa0;nm/900&#xa0;nm). In this case, 4T1 tumor&#x2013;bearing mice were injected into OTPA-TQ3 NPs intravenously for 24&#xa0;h, followed by NIR fluorescence and Raman imaging, and the vast majority of tumor tissues were removed after performing the first surgery (<xref ref-type="fig" rid="F5">Figures 5B1B2</xref>&#x2013;<xref ref-type="fig" rid="F6">6B2</xref>). Furthermore, the remaining tiny tumors with diameters of roughly 450&#xa0;&#x3bc;m after the first surgery treatment could be clearly delineated by intraoperative fluorescence&#x2013;Raman imaging, and then the residual tumors were completely resected after the second surgery until no fluorescence and Raman signals were observed (<xref ref-type="fig" rid="F5">Figures 5B3B4</xref>&#x2013;<xref ref-type="fig" rid="F6">6B4</xref>). The image-guided surgery shows that the surgeon can accurately eliminate all the small remaining tumors with quick, real-time, and sensitive fluorescence imaging and high-contrast Raman imaging with zero background and under the help of OTPA-TQ3 NPs, which increase the life span of the mice greatly post-surgery.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>
<bold>(A)</bold> Chemical structure of OTPA-TQ3. Adapted with permission from <xref ref-type="bibr" rid="B41">Qi et&#x20;al. (2019)</xref>. <bold>(B)</bold> Representative fluorescence images <bold>(B1)</bold> and Raman images <bold>(B2)</bold> of the OTPA-TQ3 NPs-handled tumor-bearing mice before and after the first surgery. Representative fluorescence images <bold>(B3)</bold> and Raman images <bold>(B4)</bold> of the OTPA-TQ3 NPs-handled tumor-bearing mice before and after the second surgery.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g005.tif"/>
</fig>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>
<bold>(A)</bold> Chemical structure of NIR-II probe H3-PEG2k. Adapted with consent from <xref ref-type="bibr" rid="B63">Zeng et&#x20;al. (2019)</xref>. <bold>(B) (B1&#x2013;B4)</bold>: The representative NIR-II fluorescence images. <bold>(B5&#x2013;B7)</bold>: NIR-II image-guided surgeries after intravenously injecting the probe. <bold>(B8)</bold>: Hematoxylin and eosin (H&#x26;E) staining of the carcinoma resected. <bold>(C)</bold> Elementary diagram of the preparation step and usage scenes of BPN-BBTD@F127 NPs. Adapted with consent from <xref ref-type="bibr" rid="B12">Fan et&#x20;al. (2021b)</xref>. <bold>(D)</bold> NIR-II fluorescence image-guided resection of bowel parts with serious inflammation.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g006.tif"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>NIR-II Fluorescence Imaging Technology for Guided Surgery</title>
<p>Fluorescent imaging of biological systems in the second near-infrared window (NIR-II) can realize micrometer-scale resolution at depths of mm and probe tissue at depths of cm, respectively (<xref ref-type="bibr" rid="B9">Ding et&#x20;al., 2018b</xref>; <xref ref-type="bibr" rid="B3">Cao et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B50">Wan et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B6">Dai et&#x20;al., 2021</xref>). NIR-II fluorescence image-guided surgical guidance offers one of the most hopeful methods.</p>
<sec id="s3-1">
<title>Mammary Carcinoma Resection</title>
<p>Xiao et&#x20;al. constructed a novel small organic molecule H3-PEG2k (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 760&#xa0;nm/1,023&#xa0;nm) as the biocompatible NIR-II fluorescence imaging agent for <italic>in vivo</italic> imaging and image-guided surgeries (<xref ref-type="fig" rid="F6">Figure&#x20;6A</xref>) (<xref ref-type="bibr" rid="B63">Zeng et&#x20;al., 2019</xref>). H3-PEG2k was administrated into a DMBA-caused mammary carcinoma rat by intravenous injection to obtain NIR-II fluorescence images of rat tumors at different time nodes (0, 1.5, 4.5, and 8&#xa0;h, <xref ref-type="fig" rid="F6">Figure&#x20;6B1&#x2013;4</xref>). The observation of great fluorescence signals was recorded at 1.5, 4.5, and 8&#xa0;h after injection, and the clear distinction of autonomous tumor description from the nearby normal tissue appeared at 8.5&#xa0;h (<xref ref-type="fig" rid="F6">Figure&#x20;6B5</xref>). The NIR-II fluorescence image-guided surgery was conducted for the complete dissection and removal of carcinoma (<xref ref-type="fig" rid="F6">Figure&#x20;6B5&#x2013;7</xref>). Hematoxylin and eosin (H&#x26;E) staining was employed to stain the fluorescent specimen of the overall tumor from the surgery, and there were large amounts of tumor cells found in the overall specimen, but scarce normal tissues were observed in the resection margin of carcinoma (<xref ref-type="fig" rid="F6">Figure&#x20;6B8</xref>). This research study offers important guidelines for preclinical research of an NIR-II fluorescent probe as the agent of treating clinical cancers.</p>
</sec>
<sec id="s3-2">
<title>Bowel Resection</title>
<p>Lin et&#x20;al. constructed a type of aggregation-caused emission (AIE) nanoprobes (BPN-BBTD@F127 nanoparticles, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 710&#xa0;nm/930&#xa0;nm) and first examined the usage value of the nanoparticles (NPs) in supervising the disease progression and the answer to drug violation in inflammatory bowel diseases (IBD) in murine models (<xref ref-type="fig" rid="F6">Figure&#x20;6C</xref>) (<xref ref-type="bibr" rid="B12">Fan et&#x20;al., 2021b</xref>). <xref ref-type="fig" rid="F6">Figure&#x20;6D</xref> shows the whole course of inflammatory bowel resection. First, strong NIR-II fluorescence was observed in the lesion through the NIR-II fluorescence imaging system. The identification of the colon, partially with great NIR-II fluorescence signals as the seriously diseased colon part (<xref ref-type="fig" rid="F6">Figure&#x20;6D1</xref>), was conducted. Second, the aseptic removal of the selective colon part was carried out under the guidance of bright NIR-II fluorescence (<xref ref-type="fig" rid="F6">Figure&#x20;6D2</xref>). After resecting the selected colon segment, there were very poor NIR-II fluorescence signals of the stored colon. The anastomosis of the existing intestinal segments with two steeks on the anterior end (<xref ref-type="fig" rid="F6">Figure&#x20;6D3</xref>) and the posterior end (<xref ref-type="fig" rid="F6">Figure&#x20;6D4</xref>) could obviously be observed. This sensitive and easy approach is greatly underlying with regard to IBD diagnosis and surgical treatment.</p>
</sec>
<sec id="s3-3">
<title>Liver Tumor Resection</title>
<p>In recent days, Tian et&#x20;al. (<xref ref-type="fig" rid="F7">Figure&#x20;7A</xref>) realized the NIR-II image-guided tumor surgeries in a man (<xref ref-type="bibr" rid="B21">Hu et&#x20;al., 2020</xref>). In their study, FDA-approved ICG (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 808&#xa0;nm/980&#xa0;nm) was adopted as the fluorophore. Integrated detectors in an optical imaging instrument can be employed to simultaneously detect both NIR-I and NIR-II emissions of ICG. Visible light imaging was first received by tumor lesions recognized by surgeons using a multispectral imaging instrument (<xref ref-type="fig" rid="F7">Figure&#x20;7B1</xref>). The location of the tumor was identified by NIR-II fluorescence (<xref ref-type="fig" rid="F7">Figure&#x20;7B2</xref>). The NIR-I fluorescence allocation mode conformed to that of the NIR-II image (<xref ref-type="fig" rid="F7">Figure&#x20;7B3</xref>). Under the guidance of ultrasonography and the visible light image, the tumor was resected and regarded as fully eliminated based on the experience of the surgeons (<xref ref-type="fig" rid="F7">Figure&#x20;7B4</xref>). Nevertheless, fluorescence was detected by NIR-II and NIR-I images from the residual tissue (<xref ref-type="fig" rid="F7">Figure&#x20;7B5,6</xref>). Then, based on the NIR-I images, the performance of more resection was evaluated. After the second resection, visual investigation showed no remaining tumor (<xref ref-type="fig" rid="F7">Figure&#x20;7B7</xref>), and optical imaging displayed no NIR-II or NIR-I fluorescence in the existing tissue either (<xref ref-type="fig" rid="F7">Figure&#x20;7B8,9</xref>). With such distinctive advantages, the new NIR-II imaging measures might be highly potential in the improvement of preoperative treatment and intraoperative guidance in the future.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>
<bold>(A)</bold> In-human liver tumor surgery under the guidance of multispectral optical imaging in the visible and NIR-I/II windows. Adapted with permission from <xref ref-type="bibr" rid="B21">Hu et&#x20;al. (2020)</xref>. <bold>(B)</bold> Intraoperative NIR-I/II fluorescence image-guided tumor resection. <bold>(C)</bold> Peptide sequence and the systematic molecular construction of CH1055-4Glu-AE105. Adapted with consent from <xref ref-type="bibr" rid="B26">Kurbegovic et&#x20;al. (2018)</xref>. <bold>(D)</bold> For both full resection <bold>(D1)</bold> and inadequate resection <bold>(D2)</bold>, left-hand end images were taken before tumor resection and right-hand end images were taken after resection.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g007.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Glioblastoma Resection</title>
<p>Cheng et&#x20;al. incorporated NIR-II fluorophore (CH1055) and urokinase plasminogen activator receptor directing peptide (AE105) to develop an oriented NIR-II fluorescent probe (CH1055-4Glu-AE105, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 750&#xa0;nm/1,055&#xa0;nm) (<xref ref-type="fig" rid="F7">Figure&#x20;7C</xref>) (<xref ref-type="bibr" rid="B26">Kurbegovic et&#x20;al., 2018</xref>). Guided by NIR-II imaging, the performance of glioblastoma (GBM) resections was evaluated. On bright area images, clear recognition of GBM could not be realized by the midline incision made at the scalp (<xref ref-type="fig" rid="F7">Figure&#x20;7D</xref>). By comparison, while imaging with NIR-II, clear visualization of the tumor was obtained with distinct description between the central tumor and the nearby tissue. On the basis of fluorescence imaging, a full resection was regarded due to a margin-to-background proportion (MBR) &#x3d; 1.0 (margin signal 36,000 Gray and background signal of 35,000 Gray) (<xref ref-type="fig" rid="F7">Figure&#x20;7D1</xref>). To be extra, an inadequate resection was conducted with an MBR &#x3d; 1.5 (residual postoperative fluorescent signal in the periphery/margin with a gray value of 52,500 and a background signal of 36,000 gray, respectively) (<xref ref-type="fig" rid="F7">Figure&#x20;7D2</xref>). Under the guidance of NIR-II fluorescence imaging, the orthotopic GBM resections were successfully conducted. As a powerful tool, peptide phage display technology could be used to identify disease-specific antigens that recognize tumor targets. The NIR-II probe and imaging setup have displayed promising preclinical outcomes and translation potential.</p>
</sec>
<sec id="s3-5">
<title>Lymph Node Resection</title>
<p>In recent days, Zhang et&#x20;al. disclosed a new measure by assembling <italic>in vivo</italic> the NIR-II&#x2013;emitting down shift nanoparticles (DCNPs, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 808&#xa0;nm/1,060&#xa0;nm) functionalized with DNA and directing peptides to enhance the image-guided surgery (<xref ref-type="fig" rid="F8">Figure&#x20;8A</xref>) (<xref ref-type="bibr" rid="B52">Wang et&#x20;al., 2018</xref>). Because there is a complementary DNA sequence in these two nanoparticles, efficient tumor retention could be achieved by the assembling. Meanwhile, the quick expulsion of dispersed nanoparticles in the normal tissues from the body by the renal excretory system could be realized because of their small scale, and the non-directed background signal was decreased further. As shown in <xref ref-type="fig" rid="F8">Figure&#x20;8B</xref>, DCNPs were successfully applied to map epidermal tumors (<xref ref-type="fig" rid="F8">Figure&#x20;8B1&#x2013;4</xref>), peritoneal metastases (<xref ref-type="fig" rid="F8">Figure&#x20;8B5&#x2013;8</xref>) and popliteal lymph node metastasis (<xref ref-type="fig" rid="F8">Figure&#x20;8B9&#x2013;12</xref>) in intraoperative mice, and fluorescence imaging-guided dissection of the abovementioned tumors in intraoperative mice by injecting DCNPs. By using DCNPs, the precisely preoperation navigation and effectively intra-operation guideline for accurately identifying the tumor margins of the tumors were smoothly actualized <italic>via</italic> NIR-II bioimaging, ensuring complete resection of the&#x20;tumor.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>
<bold>(A)</bold> Schematic explanation of NIR-II nanoprobe fabrication. <bold>(B)</bold> NIR-II fluorescence image-guided resection. NIR-II fluorescence bioimaging result of the epidermal tumor <bold>(B1,B2)</bold>, digital image <bold>(B3)</bold> and NIR-II fluorescence bioimaging result <bold>(B4)</bold> after surgical resection. The NIR-II fluorescence bioimaging result of peritoneal metastases <bold>(B5,B6)</bold>, digital image <bold>(B7),</bold> and NIR-II fluorescence bioimaging result <bold>(B8)</bold> after surgical resection. The NIR-II bioimaging outcomes of popliteal lymph node metastasis <bold>(B9,B10)</bold>. Digital image <bold>(B11)</bold> and NIR-II fluorescence bioimaging result <bold>(B12)</bold> after surgical resection. Adapted with consent from <xref ref-type="bibr" rid="B52">Wang et&#x20;al. (2018)</xref>.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g008.tif"/>
</fig>
<p>Lin et&#x20;al. developed a novel type of organic nanoprobes (IDSe-IC2F nanoparticles, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 793&#xa0;nm/1,010&#xa0;nm) with excellent NIR-II fluorescence and photothermal nature (<xref ref-type="fig" rid="F9">Figure&#x20;9A</xref>) (<xref ref-type="bibr" rid="B11">Fan et&#x20;al., 2021a</xref>). For assessing the usage value of double-channel NIR-II fluorescence imaging, Lin et&#x20;al. conducted the LNs resection directed by this imaging system. <xref ref-type="fig" rid="F9">Figure&#x20;9B1&#x2013;5</xref> showed major procedures, which could be briefly defined as follows: location identification of LNs, double-channel NIR-II fluorescence image-guided resection, confirmation of no active bleeding, and identification of no remaining LNs. The injection of TQ-BPN NPs and IDSe-IC2F NPs into the tail vein and tiny intestine follicle was conducted. With laser irradiation of 793&#xa0;nm, mesenteric LNs and the lymphatic vessels could be accurately localized and rapidly found (<xref ref-type="fig" rid="F9">Figure&#x20;9B6</xref>). Then, the main blood vessels (<xref ref-type="fig" rid="F9">Figure&#x20;9B7</xref>) were detected by turning on the 623-nm LED. Due to the double-channel NIR-II fluorescence imaging, the LNs from the blood vessels could be carefully separated (<xref ref-type="fig" rid="F9">Figure&#x20;9B8</xref>). Interestingly, the complete labeling and resection of the two LNs were conducted. Under the LED excitation of 623&#xa0;nm, whether there was active bleeding after surgery could be easily observed (<xref ref-type="fig" rid="F9">Figure&#x20;9B9</xref>). Besides, whether LNs remain in the surgical region after the irradiation of 793&#xa0;nm was also detected (<xref ref-type="fig" rid="F9">Figure&#x20;9B10</xref>). The gastric LNs (<xref ref-type="fig" rid="F9">Figure&#x20;9B11&#x2013;15</xref>) were removed with similar modality. Due to other types of NIR-II fluorescent NPs with various optical characteristics, multi-channel fluorescence image-guided surgery was smoothly performed. The introduction of photothermal ablation of metastatic LNs is made as an excellent complement to the surgery. This platform provided a new angle through which we can perform a more accurate surgery.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>
<bold>(A)</bold> Schematic illustration of preparing IDSe-IC2F NPs. <bold>(B)</bold> Double-channel NIR-II fluorescence image-guided lymphadenectomy on rats. Adapted with permission from <xref ref-type="bibr" rid="B11">Fan et&#x20;al. (2021a)</xref>.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g009.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Imaging for Osteosarcoma Resection</title>
<p>Cheng et&#x20;al. formulated a diketopyrrolopyrrole-based semiconducting polymer NP (PDFT1032, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 808&#xa0;nm/1,032&#xa0;nm) with a high tumor-to-background ratio (TBR) and smoothly applied it for tumor surgery guidance (<xref ref-type="fig" rid="F10">Figure&#x20;10A</xref>) (<xref ref-type="bibr" rid="B44">Shou et&#x20;al., 2018</xref>). The versatile application of PDFT1032 for some significant biomedical uses in the NIR-II window has been shown. For confirming the capacity of PDFT1032 in NIR-II image-guided tumor surgeries, NIR-II imaging, with great comparison (<xref ref-type="fig" rid="F10">Figure&#x20;10B1,2</xref>), was employed to visualize the mice with an orthotopic osteosarcoma. Because of the micron-sized spatial resolution and large interim resolution, NIR-II window imaging displayed large sensitivity for the delineation of the orthotopic tumor (<xref ref-type="fig" rid="F10">Figure&#x20;10B3</xref>). After completing the image-guided tumor resection, still NIR-II signals remained nearby the knee joint, which were invisible to the surgeon (<xref ref-type="fig" rid="F10">Figure&#x20;10B4&#x2013;6</xref>). Hence, all the residual lesions were eliminated by surveying the resection bed. Interestingly, the identification and complete resection of lesions, such as nearby orthotopic tumor micro-metastasis (<xref ref-type="fig" rid="F10">Figure&#x20;10B5&#x2013;7</xref>) (which was validated through histological exploration further, <xref ref-type="fig" rid="F10">Figure&#x20;10B8</xref>) and the lymph node (<xref ref-type="fig" rid="F10">Figure&#x20;10B9,10</xref>) were performed. For following up true lymphatic flow and drainage, intradermal injection of PDFT1032 was performed at the tumor margin, and the sharing of the lymphatic path with the tumor (<xref ref-type="fig" rid="F10">Figure&#x20;10C1</xref>) would be made. Ten minutes later, the clear identification of the two axillary lymph nodes was realized with the skin intact (<xref ref-type="fig" rid="F10">Figure&#x20;10C2</xref>). Guided by NIR-II imaging, the visualization and resection of sentinel lymph nodes were conducted (<xref ref-type="fig" rid="F10">Figures 10C3&#x2013;6</xref>). PDFT1032 has potential in being extensively applied in clinical imaging and surgically treating malignancy as a highly hopeful NIR-II&#x20;probe.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>
<bold>(A)</bold> Schematic explanation of PDFT1032 fabrication. Adapted with consent from <xref ref-type="bibr" rid="B44">Shou et&#x20;al. (2018)</xref>. <bold>(B) B1</bold>: Digital picture of nude mice with an orthotopic osteosarcoma. <bold>B2,B3</bold>: NIR-II images of the whole tumor. <bold>B4</bold>: Resection of the tumor body was performed. <bold>B5</bold>: Mic-NIR-II imaging. <bold>B6</bold>: Bright field photo-metastasis of the tumor. <bold>B7</bold>: NIR-II imaging was adopted to fully resect the micro-metastasis. <bold>B8</bold>: Histological analysis. The visualization and resection of the lymph node were conducted by virtue of PDFT1032 (<bold>B9,B10</bold>). <bold>(C) C1</bold>: Injection of PDFT1032 was administered at the margin of the B16F10 melanoma. <bold>C2</bold>: After 10&#xa0;min, the clear identification of two axillary lymph nodes was conducted. <bold>C3&#x2013;C5</bold>: The clear identification of effective lymphatic vessel linking the tumor to the node was performed. The distinct identification of the sentinel lymph node and the secondary lymph node was performed. <bold>C6</bold>: Resection of the sentinel lymph node was performed (inserted image). <bold>(D)</bold> Schematic construction explanation of RENPs@Lips. Adapted with consent from <xref ref-type="bibr" rid="B27">Li et&#x20;al. (2019)</xref>. <bold>(E) E1</bold>: Digital picture of nude mice with femur orthotopic osteosarcoma. <bold>E2&#x2013;E7</bold>: Guided by NIR-II, the main blood supply of osteosarcoma was obviously distinguished from the femoral artery. <bold>E8,E9</bold>: Interim blockage of the main tumor blood vessel was induced by carrying out a vessel clamp, and the signal of blood flow toward the tumor vanished, indicating the smooth realization of embolization surgery of osteosarcoma. <bold>F1</bold>: Digital picture of nude mice with xenograft melanoma. <bold>F2,F3</bold>: Visible popliteal LN and sacral LN at 6&#xa0;h after injection. <bold>F4,F5</bold>: Resection of popliteal LN. <bold>F6</bold>: histological analysis.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g010.tif"/>
</fig>
<p>Tian et&#x20;al. reported a kind of excretable NIR-II nanoparticle based on lanthanide, RENPs@Lips (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 808&#xa0;nm/1,064&#xa0;nm) (<xref ref-type="fig" rid="F10">Figure&#x20;10D</xref>) (<xref ref-type="bibr" rid="B27">Li et&#x20;al., 2019</xref>). Stimulated by the description of the tumor&#x2019;s main blood supply, intraoperative guidance for tumor vascular embolization was explored by NIR-II image-guided surgery of femur orthotopic osteosarcoma. The clear discrimination of the main blood supply of the tumor from the femoral artery (<xref ref-type="fig" rid="F10">Figures 10E2&#x2013;7</xref>) was conducted. Then, the blood flow imitating the clinical vascular embolization step (<xref ref-type="fig" rid="F10">Figure&#x20;10E8</xref>) was blocked by implementing a vessel clamp. Remarkably, the signal of the blood flow toward the tumor vanished (<xref ref-type="fig" rid="F10">Figure&#x20;10E9</xref>), indicating the smooth realization of embolization surgery for tumor blood supply. Next, a closer sentinel lymph node step in clinical practices was further mimicked under pathological conditions on nude mice with xenograft B16F10 melanoma. Six hours later, intradermal injection of RENPs@Lips was administered at the margin of the melanoma (<xref ref-type="fig" rid="F10">Figure&#x20;10F1</xref>), and the sentinel lymph node and secondary lymph node were highly visible (<xref ref-type="fig" rid="F10">Figure&#x20;10F2,3</xref>). Guided by NIR-II, the precise dissection of the sentinel lymph node was performed quickly (<xref ref-type="fig" rid="F10">Figure&#x20;10F4,5</xref>), and the histological analysis determined that there was melanoma metastasis in the sentinel lymph node (<xref ref-type="fig" rid="F10">Figure&#x20;10F6</xref>). RENPs@Lips performs well in the identification of orthotopic tumor vessels intraoperatively and NIR-II image-guided embolization surgery.</p>
<p>Functionalized red blood cells with amine-modified upconversion nanoparticles (UCNPs) were fabricated by Liu et&#x20;al. as a red blood cell&#x2013;based multimodal probe (RBCp, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 808 and 980&#xa0;nm/835&#xa0;nm) for NIR-II luminescence-guided accurate tumor resection with a laser irradiation of 808 or 980-nm and laser activated O<sub>2</sub> production to assist PDT treatment for popliteal lymph node metastasis (<xref ref-type="fig" rid="F11">Figure&#x20;11A</xref>) (<xref ref-type="bibr" rid="B53">Wang et&#x20;al., 2019</xref>). NIR-II bioimaging can be employed for the visualization of the full summary of tumors with &#x223c;7 and &#x223c;3&#xa0;mm<sup>3</sup> in this superior time window (<xref ref-type="fig" rid="F11">Figure&#x20;11B1,3</xref>). Guiding NIR-II fluorescence bioimaging, the investigation into H&#x26;E staining was conducted after resecting all tumors, indicating the accurate recognition of tumor margins with various volumes (<xref ref-type="fig" rid="F11">Figure&#x20;11B2,4</xref>). In addition, the intraoperative imaging application of the RBCp in a liver popliteal lymph node metastasis model indicates that the metastatic lesion could be precisely identified as well as totally removed by the guidance of NIR-II fluorescence bioimaging in the optimal surgical window. Thus, the RBCp could illustrate accurate identification of solid tumor margins for the guidance and optimization of therapeutic&#x20;steps.</p>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>
<bold>(A)</bold> Schematic illustration of red blood cell&#x2013;based probe (RBCp) fabrication. Adapted with consent from <xref ref-type="bibr" rid="B53">Wang P. et&#x20;al. (2019)</xref>. <bold>(B)</bold> NIR-II fluorescence bioimaging outcomes (12&#xa0;h PI) of epidermal tumors with scales of 7&#xa0;mm<sup>3</sup> <bold>(B1)</bold> and 3&#xa0;mm<sup>3</sup> <bold>(B3)</bold> and NIR-II fluorescence bioimaging outcomes after surgically resecting the tumors. <bold>(B2,B4)</bold> H&#x26;E staining outcomes of the tumor and normal tissue border in <bold>B1</bold> and <bold>B3</bold>. <bold>(C)</bold> Integration and self-assembly of NIR-II probes <italic>via</italic> PEGylation: SCH1&#x2013;SCH4 with scales varying from the nanoparticle to molecule. Adapted with permission from <xref ref-type="bibr" rid="B8">Ding et&#x20;al., 2018a</xref>). <bold>(D) D1</bold>: Image-guided surgery of the HepG2 tumor after intravenously injecting SCH4. <bold>D2</bold>: H&#x26;E staining images of the resected tumor tissue. <bold>(E)</bold> Construction of <sup>68</sup>Ga-CHS2. Adapted with permission from <xref ref-type="bibr" rid="B45">Sun et&#x20;al. (2018)</xref>. <bold>(F) (F1&#x2013;F5)</bold> U87MG tumor description and image-guided surgery at 12&#xa0;h after the tail vein injection of CHS2. <bold>(F6)</bold> H&#x26;E staining outcomes of the tumor. <bold>(G)</bold> Chemical structure of IR-BEMC6P and the conjugate plan of IR-BEMC6P@TATE. Adapted with permission from <xref ref-type="bibr" rid="B31">Liu et&#x20;al. (2021)</xref>. <bold>(H) H1</bold>: NIR-II imaging of the IR-BEMC6P@TATE injection after being blocked by the TATE peptide only. Digital picture of the tumor xenograft mouse model before <bold>(H2)</bold> and after <bold>(H3)</bold> NIR-II guided surgeries. <bold>H4</bold>: NIR-II image-guided surgeries for excising the&#x20;tumor.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g011.tif"/>
</fig>
<p>Sun et&#x20;al. formulated a unique PEGylation measure and researched the association between the molecular scale and physical and chemical features (<xref ref-type="fig" rid="F11">Figure&#x20;11C</xref>) (<xref ref-type="bibr" rid="B8">Ding et&#x20;al., 2018a</xref>). They applied the CH1055 scaffold as the reference for the accurate adjustment of the NIR-II dyes (SCH1&#x2013;SCH4) from single molecules to nanoparticles, which perform excellent pharmacokinetics and great tumor uptake of organic small molecular probes using the PEGylation strategy. Due to excellent photostability and urine excretion of SCH4 (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 739&#xa0;nm/1,050&#xa0;nm), it was employed for recognizing the liver tumor and guiding the surgery. The clear distinction of tumor delineation from normal tissues was made successfully, and the tumor tissues were completely treated and removed, along with the decrease of the SBR value from 7.2 to 1.1 (<xref ref-type="fig" rid="F11">Figure&#x20;11D1</xref>). After this surgery, the surgical tumor tissues were histologically analyzed, which indicated the features of cancer histology (<xref ref-type="fig" rid="F11">Figure&#x20;11D2</xref>). Furthermore, SCH4 was also applied to the detection of liver fibrosis distinguished from the surrounding normal tissues in the NIR-II region. Thus, SCH4 can be promising in the research study on animal liver disease models.</p>
<p>The NIR-II/PET probe <sup>68</sup>Ga-CHS2 (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 808&#xa0;nm/1,055&#xa0;nm) was generated by Sun et&#x20;al., which could enhance surgical accuracy with a superior SBR value (<xref ref-type="fig" rid="F11">Figure&#x20;11E</xref>) (<xref ref-type="bibr" rid="B45">Sun et&#x20;al., 2018</xref>). They formulated a novel dual-mode imaging platform which adds thiols to propylamine stents with base catalysis, realizing various efficient and selectively assembled thiol units with no protective measures. PET imaging and NIR-II FI were conducted on U87Mg-tumor&#x2013;bearing mice by <sup>68</sup>Ga-CHS2. Motivated by these hopeful outcomes obtained in <italic>in vivo</italic> PET/NIR-II images, the in-depth evaluation of CHS2 was conducted for follow-up of the accurate description of tumor lesions, resection margins, and image-guided surgeries. The injection of U87MG tumor&#x2013;bearing mice was administered with 100&#xa0;mg of CHS2, and the notable identification of tumor description could be realized from the tumor-bearing mice. The SBR value was 4.75&#x20;&#xb1; 0.22 at 12&#xa0;h after injection, and while dissecting and removing the tumor from the soft tissue in the leg area, the SBR value declined to 1.16&#x20;&#xb1; 0.27, showing thorough dissection of the tumor (<xref ref-type="fig" rid="F11">Figure&#x20;11F1&#x2013;5</xref>). After this surgery, surgical tumor tissues were also histologically analyzed, and the features of cancer histology were confirmed (<xref ref-type="fig" rid="F11">Figure&#x20;11F6</xref>).</p>
<p>Guided by NIR-II imaging and white light, Chen et&#x20;al. conducted a tumor excision surgery using an NIR-II fluorophore (IR-BEMC6P, <italic>&#x3bb;</italic>
<sub>ex</sub>/<italic>&#x3bb;</italic>
<sub>em</sub>, 808&#xa0;nm/1,025&#xa0;nm) conjugating octreotate (TATE) peptide with outstanding optical and biological properties, such as high quantum yield (1.8%), rapid renal excretion, and minimal hepatic uptake (<xref ref-type="fig" rid="F11">Figure&#x20;11G</xref>) (<xref ref-type="bibr" rid="B31">Liu et&#x20;al., 2021</xref>). The AR42J tumor mice injected with a blockage dose of the free IR-BEMC6P without conjugation of TATE showed a very low tumor fluorescence signal, proving the specific tumor-targeting ability of IR-BEMC6P@TATE (<xref ref-type="fig" rid="F11">Figure&#x20;11H1</xref>). Besides, a tumor excision surgery was conducted with collaborative NIR-II imaging and white light guidance, which is of advantage to reduce interference and clearly distinct the tumor margin (<xref ref-type="fig" rid="F11">Figure&#x20;11H2&#x2013;4</xref>). The peptide IR-BEMC6P@(RGD, TATE) probes could quickly be excreted renally by comparison with the long-time liver cumulation of representative antibody&#x2013;dye conjugates. These quickly excreted, greatly secure integrin/somatostatin receptors targeting NIR-II probes promote the clinical interpretation of NIR-II molecular imaging in diagnosing cancer and performing imaging guidance for treatment.</p>
</sec>
<sec id="s3-7">
<title>Imaging for Peritoneal Tumor Resection</title>
<p>Tang et&#x20;al. synthesized the Janus NIR-II molecule 2TT-m, oC6B, further wrapped in the amphiphilic polymer DSPE-PEG<sub>2000</sub> affording 2TT-m, oC6B nanoparticles (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 777&#xa0;nm/1,059&#xa0;nm) for tumor NIR-II image-guided surgery (<xref ref-type="fig" rid="F12">Figure&#x20;12A</xref>) (<xref ref-type="bibr" rid="B31">Liu et&#x20;al., 2021</xref>). For manifesting the feasibility of 2TT-m, oC6B NPs to distinguish the stubborn tumor, the peritoneal carcinomatosis&#x2013;bearing murine model was used because of the presence of a lot of tumor modules of different scales in the peritoneal cavity. According to <xref ref-type="fig" rid="F12">Figure&#x20;12B1</xref>, there was well-overlapping of the fluorescence signal with the bioluminescence signal because of the improved permeability and retention (EPR) role and large brightness of the NIR-II AIEgen NPs. There was a research study conducted on the usage of 2TT-m, oC6B NPs for fluorescence-guided tumor resection. According to <xref ref-type="fig" rid="F12">Figure&#x20;12B1</xref>, with no guidance of the fluorescence signal, many relatively large tumor nodules with diameter &#x3e;1&#xa0;mm were eliminated by the surgeon. Nevertheless, a lot of dispersive fluorescence signals were observed in the peritoneal cavity after the unguided surgery, showing the residual tumor nodules. Directed by the NIR-II fluorescence signal, a second surgery was conducted, so as to eliminate tiny tumor nodules indistinguishable to surgeons. With large brightness of 2TT-m, oC6B NPs, tumor nodules in fluorescence signal-guided surgery (<xref ref-type="fig" rid="F12">Figure&#x20;12B1</xref>) were fully removed by the surgeon, which was determined by the bioluminescence image taken again after the surgery. There was thorough overlapping of bioluminescence and fluorescence signals of the eliminated nodules (<xref ref-type="fig" rid="F12">Figure&#x20;12B2</xref>), showing the precision of the surgery. It should be noted that more tiny tumor nodules with diameter &#x3c;1&#xa0;mm than that of the unguided group were resected by the surgeon significantly (<xref ref-type="fig" rid="F12">Figure&#x20;12B3</xref>), displaying improved surgery precision by NIR-II fluorescence.</p>
<fig id="F12" position="float">
<label>FIGURE 12</label>
<caption>
<p>
<bold>(A)</bold> Preparation of 2TT-m, oC6B NPs with amphiphilic polymer DSPE-PEG<sub>2000</sub>. Adapted with permission from ref (<xref ref-type="bibr" rid="B32">Liu et&#x20;al., 2020</xref>). <bold>(B) B1</bold>: Bioluminescence and NIR-II imaging of the abdominal cavity before and after resecting the tumor. <bold>B2</bold>: Bioluminescence and NIR-II fluorescence signals of eliminated nodules of unguided and 2TT-m, oC6B NPs&#x2013;guided groups. <bold>B3</bold>: Histogram of nodule diameters resected from fluorescence-guided and -unguided groups. <bold>(C)</bold> Schematic illustration of fabricating pNIR4-PAE NPs. Adapted with permission from <xref ref-type="bibr" rid="B54">Wen et&#x20;al. (2019)</xref>. <bold>(D) D1</bold>: Bioluminescence and NIR-II imaging of the abdominal cavity before and after resecting the tumor. <bold>D2</bold>: Bioluminescence and NIR-II imaging of the resected nodules of unguided and pNIR4-PAE NPs&#x2013;guided groups. <bold>D3</bold>: Statistical information of the resected nodule diameters. <bold>(E)</bold> Schematic explanation of the NIR-II fluorescent nanochain probe APP-Ag<sub>2</sub>S-RGD for image-guided peritoneal carcinomatosis surgeries. Adapted with permission from <xref ref-type="bibr" rid="B30">Ling et&#x20;al., 2020</xref>. <bold>(F) F1</bold>: Bioluminescence and NIR-II pictures for preoperative and intraoperative phases after IP governance of either Ag<sub>2</sub>S-RGD or APP-Ag<sub>2</sub>S-RGD. <bold>F2</bold>: NIR-II fluorescence images of tumor nodules excised with the naked eye (i) and NIR-II fluorescent imaging guidance (ii: Ag<sub>2</sub>S-RGD, iii: APP-Ag<sub>2</sub>S-RGD); iv) bright-field image associated with the (iii). F3: Bright-field and fluorescence images of the tumor slice procured from the APP-Ag<sub>2</sub>S-RGD-guided surgery using a multi-channel fluorescence microscope. <bold>(G)</bold> Schematic illustration of constructing FEAD1 and ability to accurately diagnose and treat the tumor in peritoneal metastasis. Adapted with consent from <xref ref-type="bibr" rid="B30">Ling et&#x20;al. (2020)</xref>. <bold>(H) H1</bold>: NIR-II and bioluminescence imaging of preoperative phasing of intraperitoneally injecting the peritoneal metastasis model of FEAD1. <bold>H2</bold>: NIR-II fluorescent and bioluminescence imaging of tumor nodules excised. <bold>H3</bold>: H&#x26;E staining of the tumor slice. <bold>H4</bold>: Fluorescence imaging of the tumor slice procured from the tumor nodules excised.</p>
</caption>
<graphic xlink:href="fbioe-09-768698-g012.tif"/>
</fig>
<p>Very recently, the same group displayed that NIR-II fluorescence intensity of semiconducting polymers could be effectively improved by structure planarization (<xref ref-type="bibr" rid="B54">Wen et&#x20;al., 2019</xref>). This research study successfully actualized the high-definition vascular visualization in the NIR-II window with a planar and tortuous polymer pNIR-4 (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 750&#xa0;nm/1,040&#xa0;nm) (<xref ref-type="fig" rid="F12">Figure&#x20;12C</xref>). Tumor cells both <italic>in&#x20;vitro</italic> and <italic>in vivo</italic> were employed to efficiently internalize the pNIR4-PAE NPs activated for positive charging in a tumor microenvironment, which is conducive to accurate tumor imaging. After intravenously injecting pNIR4-PAE NPs, the perfect co-localization of NIR-II fluorescence of pNIR4-PAE NPs and the bioluminescence signal of luciferase was observed in the peritoneal cavity (<xref ref-type="fig" rid="F12">Figure&#x20;12D1</xref>), showing the precise tumor treatment of pNIR4-PAE NPs. After the second round of surgery with the guidance of NIR-II fluorescence, there was reduced tumor pressure. Verified by the bioluminescence signals of all tumor nodules harvested, the tissue resected was actually a tumor, showing the accuracy of the cancer surgery by virtue of pNIR4-PAE NPs (<xref ref-type="fig" rid="F12">Figure&#x20;12D2</xref>). Through the quantification of the diameters of the tumor nodules excised, the excision of a more sub-millimeter tumor has been performed under the guidance of intraoperative imaging (<xref ref-type="fig" rid="F12">Figure&#x20;12D3</xref>). While promoting the precise recognition of sub-millimeter tumor nodules, pNIR4-PAE NPs can greatly decrease the risk of <italic>in situ</italic> tumor re-occurrence.</p>
<p>Wang et&#x20;al. achieved accurate tumor removal in peritoneal metastasis by developing an effective measure and creating a new NIR-II fluorescent nanochain probe, APP-Ag<sub>2</sub>S-RGD (&#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 808&#xa0;nm/1,200&#xa0;nm) (<xref ref-type="fig" rid="F12">Figure&#x20;12E</xref>) (<xref ref-type="bibr" rid="B30">Ling et&#x20;al., 2020</xref>). The NIR-II fluorescence signal was obtained with preoperation and intraoperation conditions for the detection of the directing roles of APP-Ag<sub>2</sub>S-RGD and Ag<sub>2</sub>S-RGD (<xref ref-type="fig" rid="F12">Figure&#x20;12F1</xref>). By comparing with the mice handled with Ag<sub>2</sub>S-RGD, the NIR-II fluorescence intensity of the tumor handled with APP-Ag<sub>2</sub>S-RGD was greatly enhanced, and the clear identification of the tumor border was realized. After excising tumors with the guidance of NIR-II fluorescence, quantifying the fluorescence intensity of the tumor nodules showed a super high signal proportion between the tumor and normal tissues with APP-Ag<sub>2</sub>S-RGD over Ag<sub>2</sub>S-RGD (<xref ref-type="fig" rid="F12">Figure&#x20;12F2</xref>). Besides, according to fluorescence co-localization images of the tumor provided by the APP-Ag<sub>2</sub>S-RGD-guided surgery, tumor tissues with a great growth in nuclear density show a great NIR-II fluorescence signal, whereas it displayed an inappreciable fluorescence signal among normal tissues (<xref ref-type="fig" rid="F12">Figure&#x20;12F3</xref>). With the benefits from its flexible geometry and multivalent direction and its distinct NIR-II fluorescent nature, intraperitoneally injecting APP-Ag<sub>2</sub>S-RGD shows great investigation sensitivity while performing surgery on the&#x20;tumor.</p>
<p>After that, a tumor microenvironment (TME)&#x2013;activated NIR-II nanotheranostic system (FEAD1, &#x3bb;<sub>
<italic>ex</italic>
</sub>/&#x3bb;<sub>
<italic>em</italic>
</sub>, 1,094&#xa0;nm/1,200&#xa0;nm) (<xref ref-type="fig" rid="F12">Figure&#x20;12G</xref>) was developed by the same group (<xref ref-type="bibr" rid="B30">Ling et&#x20;al., 2020</xref>). The preparation of FEAD1 was conducted by the integration into mercaptopropionic-functionalized Ag<sub>2</sub>S (MPA-Ag<sub>2</sub>S) QDs, DOX, NIR absorber A1094, and peptide Fmoc-His into nanoparticles. After injecting FEAD1 into the mice abdomen, the detection of NIR-II fluorescence signals and bioluminescence signals was performed (<xref ref-type="fig" rid="F12">Figure&#x20;12H1</xref>). The fluorescent signal gradually grew over time to become maximum (TBR about 7) at 2&#xa0;h after injection. Guided by the NIR-II fluorescence, the clear profile and excision of metastatic nodules could be conducted (<xref ref-type="fig" rid="F12">Figure&#x20;12H2</xref>). Besides, normative H&#x26;E staining was carried out, verifying that the excised nodules were composed of tumor tissues (<xref ref-type="fig" rid="F12">Figure&#x20;12H3</xref>). Moreover, fluorescence co-localization images of the tumor from the FEAD1-guided excision displayed that tumor tissues with a great growth in nuclear density produce great fluorescence signals from both NIR-II Ag<sub>2</sub>S QD and DOX, whereas healthy tissues (<xref ref-type="fig" rid="F12">Figure&#x20;12H4</xref>) emit negligible fluorescence. FEAD1 has high specificity in lighting up the peritoneal metastasis tumor nodules with large sensitivity.</p>
</sec>
</sec>
<sec id="s4">
<title>Summary and Outlook</title>
<p>In this article, we have emphasized recent prime examples of NIR-I/II fluorescence imaging for surgical navigation and the applications in various surgical resections, including orthotopic osteosarcoma, orthotopic liver tumor, orthotopic breast tumor, renal cell carcinoma, brain tumor, inflammatory bowel disease, peritoneal carcinomatosis, metastatic ovarian cancer, and lymph node. NIR-I/II dyes are capable of offering imaging of deeper tissues, and the activatable approach can achieve higher SBR between diseased tissues and normal tissues. Despite the progress showed above, several ongoing challenges shall be acknowledged and settled. 1) To expand the applications of NIR image-guided surgery from preclinical molecular imaging in experimental animal models to clinical research studies, it is essential to know the complicated systems and pathways in living organisms. Of course, reducing the potential toxicity of imaging reagents and excretion efficiency of imaging reagents by renal and hepatic clearance systems in human physiology is also of great importance to the clinical translation. 2) Moreover, there is a shortage of NIR fluorescent probes with targeting ability that has been recognized by clinical doctors, resulting in the limitation of complete visualization of constructions during image-guided surgery. Thus, it is necessary to develop new fluorescent probes with targeting groups to obtain more accurate image-guided surgery. 3) A comprehensive diagnostic system integrating NIR fluorescence imaging and other in-depth penetration imaging modalities will realize more effective investigation and surgery of cancer or other lesions by comparison with single-mode imaging. For instance, photoacoustic imaging, MRI, and CT will also enhance the imaging depth. Taken together, developing NIR probes with superior performance is of great significance and application value for tackling challenges in surgical navigation applications, and some methodological guidance strategies to improve the performance of NIR probes are summarized as following: 1) Expanding the NIR fluorophore-conjugated structure through plane direction instead of chain direction, which can improve the stability and expand the emission spectra simultaneously. 2) Incorporating water-soluble groups (such as sulfonic- and carboxylic acid moieties) into fluorophore structure or nano-modification of small-molecule organic probes to enhance the structure-inherent cancer targeting ability as well as improve the water solubility. 3) NIR fluorescent probes conjugate with other imaging agents, and dual-modal imaging such as FL/PA, FL/BL, or FL/MR imaging can be achieved at the same time, which can improve the accuracy of biomarker detection and disease diagnosis. 4) Introducing a pro-drug into the NIR probes could enable both real-time imaging-guided delivery and pro-drug activation, enhancing therapeutic outcomes and reducing side effects. In conclusion, it is expected that this review will be effective in creating new NIR I/II fluorescent probes and providing more effective and precise guidance in surgical oncology for excellent surgical results.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Author Contributions</title>
<p>LH and LY conceived this manuscript. SL, DC, LH, and LY wrote and edited this manuscript. All authors approved the manuscript for publication.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>The National Natural Science Foundation of China (21904035), China Postdoctoral Science Foundation (2020T130184), and the Hunan Provincial Natural Science Foundation of China (2020JJ5033) and start-up funds of the University of South China (201RGC012) financially supported this&#x20;study.</p>
</sec>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>H.-W.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.-D.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.-Z.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>W.-Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Near-Infrared Peptide Probe with Tumor-specific Excretion-Retarded Effect for Image-Guided Surgery of Renal Cell Carcinoma</article-title>. <source>ACS Nano</source> <volume>14</volume>, <fpage>927</fpage>&#x2013;<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.9b08209</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 countriesGLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>. <source>CA: A Cancer J.&#x20;Clinicians</source> <volume>68</volume>, <fpage>394</fpage>&#x2013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21492</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Recent Progress in NIR-II Contrast Agent for Biological Imaging</article-title>. <source>Front. Bioeng. Biotechnol.</source> <volume>7</volume>, <fpage>487</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2019.00487</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Calixarene&#x2010;Based Supramolecular AIE Dots with Highly Inhibited Nonradiative Decay and Intersystem Crossing for Ultrasensitive Fluorescence Image&#x2010;Guided Cancer Surgery</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>59</volume>, <fpage>10008</fpage>&#x2013;<lpage>10012</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201916430</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curry</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Krist</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>D. K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Annual Report to the Nation on the Status of Cancer, Part II: Recent Changes in Prostate Cancer Trends and Disease Characteristics</article-title>. <source>Cancer</source> <volume>125</volume>, <fpage>317</fpage>&#x2013;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.31846</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Small Molecular NIR-II Fluorophores for Cancer Phototheranostics</article-title>. <source>The Innovation</source> <volume>2</volume>, <fpage>100082</fpage>. <pub-id pub-id-type="doi">10.1016/j.xinn.2021.100082</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Groot</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>B. W.</given-names>
</name>
<name>
<surname>Munden</surname>
<given-names>R. F.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The Epidemiology of Lung Cancer</article-title>. <source>Transl. Lung Cancer Res.</source> <volume>7</volume>, <fpage>220</fpage>&#x2013;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.21037/tlcr.2018.05.06</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2018a</year>). <article-title>PEGylation Regulates Self&#x2010;Assembled Small&#x2010;Molecule Dye-Based Probes from Single Molecule to Nanoparticle Size for Multifunctional NIR&#x2010;II Bioimaging</article-title>. <source>Adv. Healthc. Mater.</source> <volume>7</volume>, <fpage>1800973</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.201800973</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>Recent Advances in Near-Infrared II Fluorophores for Multifunctional Biomedical Imaging</article-title>. <source>Chem. Sci.</source> <volume>9</volume>, <fpage>4370</fpage>&#x2013;<lpage>4380</lpage>. <pub-id pub-id-type="doi">10.1039/c8sc01153b</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esserman</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>I. M.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Reid</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Overdiagnosis and Overtreatment in Cancer</article-title>. <source>JAMA</source> <volume>310</volume>, <fpage>797</fpage>&#x2013;<lpage>798</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.108415</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>Nanoprobes&#x2010;Assisted Multichannel NIR&#x2010;II Fluorescence Imaging&#x2010;Guided Resection and Photothermal Ablation of Lymph Nodes</article-title>. <source>Adv. Sci.</source> <volume>8</volume>, <fpage>2003972</fpage>. <pub-id pub-id-type="doi">10.1002/advs.202003972</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Aggregation&#x2010;Induced Emission (AIE) Nanoparticles&#x2010;Assisted NIR&#x2010;II Fluorescence Imaging&#x2010;Guided Diagnosis and Surgery for Inflammatory Bowel Disease (IBD)</article-title>. <source>Adv. Healthc. Mater.</source>, <fpage>2101043</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202101043</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faubert</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Solmonson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>DeBerardinis</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Metabolic Reprogramming and Cancer Progression</article-title>. <source>Science</source> <volume>368</volume>, <fpage>eaaw5473</fpage>. <pub-id pub-id-type="doi">10.1126/science.aaw5473</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feher</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sinusas</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Quantitative Assessment of Coronary Microvascular Function</article-title>. <source>Circ. Cardiovasc. Imaging</source> <volume>10</volume>. <pub-id pub-id-type="doi">10.1161/CIRCIMAGING.117.006427</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>R.-M.</given-names>
</name>
<name>
<surname>Zong</surname>
<given-names>Y.-N.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.-M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.-H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics</article-title>. <source>Cancer Commun.</source> <volume>39</volume>, <fpage>22</fpage>. <pub-id pub-id-type="doi">10.1186/s40880-019-0368-6</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Boosting Photoacoustic Effect via Intramolecular Motions Amplifying Thermal&#x2010;to&#x2010;Acoustic Conversion Efficiency for Adaptive Image&#x2010;Guided Cancer Surgery</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>60</volume>, <fpage>21047</fpage>&#x2013;<lpage>21055</lpage>. <pub-id pub-id-type="doi">10.1002/anie.202109048</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanahan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Hallmarks of Cancer: the Next Generation</article-title>. <source>Cell</source> <volume>144</volume>, <fpage>646</fpage>&#x2013;<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Crucial Breakthrough of Second Near-Infrared Biological Window Fluorophores: Design and Synthesis toward Multimodal Imaging and Theranostics</article-title>. <source>Chem. Soc. Rev.</source> <volume>47</volume>, <fpage>4258</fpage>&#x2013;<lpage>4278</lpage>. <pub-id pub-id-type="doi">10.1039/c8cs00234g</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van Manen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Debie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mieog</surname>
<given-names>J.&#x20;S. D.</given-names>
</name>
<name>
<surname>Vahrmeijer</surname>
<given-names>A. L.</given-names>
</name>
</person-group>
<collab>Jan Sven David Mieog</collab>
<collab>Alexander Lucas Vahrmeijer</collab> (<year>2019</year>). <article-title>Latest Developments in Molecular Tracers for Fluorescence Image-Guided Cancer Surgery</article-title>. <source>Lancet Oncol.</source> <volume>20</volume>, <fpage>e354</fpage>&#x2013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(19)30317-1</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>El Fakhri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kuang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H. S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Real-Time Imaging of Brain Tumor for Image-Guided Surgery</article-title>. <source>Adv. Healthc. Mater.</source> <volume>7</volume>, <fpage>1800066</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.201800066</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>First-in-human Liver-Tumour Surgery Guided by Multispectral Fluorescence Imaging in the Visible and Near-Infrared-I/II Windows</article-title>. <source>Nat. Biomed. Eng.</source> <volume>4</volume>, <fpage>259</fpage>&#x2013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41551-019-0494-0</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Activatable Molecular Probes for Second Near&#x2010;Infrared Fluorescence, Chemiluminescence, and Photoacoustic Imaging</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>59</volume>, <fpage>11717</fpage>&#x2013;<lpage>11731</lpage>. <pub-id pub-id-type="doi">10.1002/anie.202001783</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dorlhiac</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Landry</surname>
<given-names>M. P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Advances in Engineering Near-Infrared Luminescent Materials</article-title>. <source>iScience</source> <volume>24</volume>, <fpage>102156</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2021.102156</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>G. K.</given-names>
</name>
<name>
<surname>Kashiwagi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Near-infrared Fluorescence Imaging in Immunotherapy</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>167</volume>, <fpage>121</fpage>&#x2013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2020.06.012</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamzan</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>When Less Is More</article-title>. <source>Adv. Pediatr.</source> <volume>68</volume>, <fpage>21</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.yapd.2021.05.013</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurbegovic</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Juhl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Leth</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<etal/>
</person-group>
<collab>Julie Maja Leth</collab> (<year>2018</year>). <article-title>Molecular Targeted NIR-II Probe for Image-Guided Brain Tumor Surgery</article-title>. <source>Bioconjug. Chem.</source> <volume>29</volume>, <fpage>3833</fpage>&#x2013;<lpage>3840</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00669</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Excretable Lanthanide Nanoparticle for Biomedical Imaging and Surgical Navigation in the Second Near&#x2010;Infrared Window</article-title>. <source>Adv. Sci.</source> <volume>6</volume>, <fpage>1902042</fpage>. <pub-id pub-id-type="doi">10.1002/advs.201902042</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Activity&#x2010;Based NIR Enzyme Fluorescent Probes for the Diagnosis of Tumors and Image&#x2010;Guided Surgery</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>60</volume>, <fpage>17268</fpage>&#x2013;<lpage>17289</lpage>. <pub-id pub-id-type="doi">10.1002/anie.202009796</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Aminopeptidase N Activatable Fluorescent Probe for Tracking Metastatic Cancer and Image-Guided Surgery via <italic>In Situ</italic> Spraying</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>142</volume>, <fpage>6381</fpage>&#x2013;<lpage>6389</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.0c01365</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ling</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Tumor Microenvironment&#x2010;Activated NIR&#x2010;II Nanotheranostic System for Precise Diagnosis and Treatment of Peritoneal Metastasis</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>59</volume>, <fpage>7219</fpage>&#x2013;<lpage>7223</lpage>. <pub-id pub-id-type="doi">10.1002/anie.202000947</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chuah</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A Two-In-One Janus NIR-II AIEgen with Balanced Absorption and Emission for Image-Guided Precision Surgery</article-title>. <source>Mater. Today Bio</source> <volume>10</volume>, <fpage>100087</fpage>. <pub-id pub-id-type="doi">10.1016/j.mtbio.2020.100087</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Planar and Twisted Molecular Structure Leads to the High Brightness of Semiconducting Polymer Nanoparticles for NIR-IIa Fluorescence Imaging</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>142</volume>, <fpage>15146</fpage>&#x2013;<lpage>15156</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.0c07193</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.-W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A "Double-Locked" and Enzyme-Activated Molecular Probe for Accurate Bioimaging and Hepatopathy Differentiation</article-title>. <source>Chem. Sci.</source> <volume>10</volume>, <fpage>10931</fpage>&#x2013;<lpage>10936</lpage>. <pub-id pub-id-type="doi">10.1039/c9sc03628h</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luciano</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Namgoong</surname>
<given-names>J.-M.</given-names>
</name>
<name>
<surname>Nani</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>S.-H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>I. H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A Biliary Tract-specific Near-Infrared Fluorescent Dye for Image-Guided Hepatobiliary Surgery</article-title>. <source>Mol. Pharmaceutics</source> <volume>16</volume>, <fpage>3253</fpage>&#x2013;<lpage>3260</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00453</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mangeolle</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yakavets</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Marchal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Debayle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pons</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bezdetnaya</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Fluorescent Nanoparticles for the Guided Surgery of Ovarian Peritoneal Carcinomatosis</article-title>. <source>Nanomaterials</source> <volume>8</volume>, <fpage>572</fpage>&#x2013;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.3390/nano8080572</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagaya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>Y. A.</given-names>
</name>
<name>
<surname>Choyke</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Fluorescence-Guided Surgery</article-title>. <source>Front. Oncol.</source> <volume>7</volume>, <fpage>314</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2017.00314</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.-L.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>X.-S.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Near-Infrared Afterglow Luminescent Aggregation-Induced Emission Dots with Ultrahigh Tumor-To-Liver Signal Ratio for Promoted Image-Guided Cancer Surgery</article-title>. <source>Nano Lett.</source> <volume>19</volume>, <fpage>318</fpage>&#x2013;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.8b03936</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Ly</surname>
<given-names>Q. P.</given-names>
</name>
<name>
<surname>Mohs</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation</article-title>. <source>Mol. Imaging Biol.</source> <volume>21</volume>, <fpage>200</fpage>&#x2013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1007/s11307-018-1239-2</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owens</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Henary</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>El Fakhri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H. S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Tissue-Specific Near-Infrared Fluorescence Imaging</article-title>. <source>Acc. Chem. Res.</source> <volume>49</volume>, <fpage>1731</fpage>&#x2013;<lpage>1740</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.6b00239</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>J.&#x20;W. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Dragonfly-shaped Near-Infrared AIEgen with Optimal Fluorescence Brightness for Precise Image-Guided Cancer Surgery</article-title>. <source>Biomaterials</source> <volume>248</volume>, <fpage>120036</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120036</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>J.&#x20;W. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Boosting Fluorescence-Photoacoustic-Raman Properties in One Fluorophore for Precise Cancer Surgery</article-title>. <source>Chem</source> <volume>5</volume>, <fpage>2657</fpage>&#x2013;<lpage>2677</lpage>. <pub-id pub-id-type="doi">10.1016/j.chempr.2019.07.015</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kandawa-Schulz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Tuning the Near Infrared II Emitting Wavelength of Small Molecule Dyes by Single Atom Alteration</article-title>. <source>Chem. Commun.</source> <volume>56</volume>, <fpage>523</fpage>&#x2013;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1039/c9cc08434g</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rawla</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Epidemiology of Prostate Cancer</article-title>. <source>World J.&#x20;Oncol.</source> <volume>10</volume>, <fpage>63</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.14740/wjon1191</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Diketopyrrolopyrrole-based Semiconducting Polymer Nanoparticles Forin Vivosecond Near-Infrared Window Imaging and Image-Guided Tumor Surgery</article-title>. <source>Chem. Sci.</source> <volume>9</volume>, <fpage>3105</fpage>&#x2013;<lpage>3110</lpage>. <pub-id pub-id-type="doi">10.1039/c8sc00206a</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery</article-title>. <source>Chem. Sci.</source> <volume>9</volume>, <fpage>2092</fpage>&#x2013;<lpage>2097</lpage>. <pub-id pub-id-type="doi">10.1039/c7sc04774f</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suurs</surname>
<given-names>F. V.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>S.-Q.</given-names>
</name>
<name>
<surname>Yim</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Schr&#xf6;der</surname>
<given-names>C. P.</given-names>
</name>
<name>
<surname>Timmer-Bosscha</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bensen</surname>
<given-names>E. S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Fluorescent Image-Guided Surgery in Breast Cancer by Intravenous Application of a Quenched Fluorescence Activity-Based Probe for Cysteine Cathepsins in a Syngeneic Mouse Model</article-title>. <source>EJNMMI Res.</source> <volume>10</volume>, <fpage>111</fpage>. <pub-id pub-id-type="doi">10.1186/s13550-020-00688-0</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery</article-title>. <source>Mol. Imaging Biol.</source> <volume>22</volume>, <fpage>476</fpage>&#x2013;<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1007/s11307-019-01389-4</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torre</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Bray</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lortet-Tieulent</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Global Cancer Statistics, 2012</article-title>. <source>CA: A Cancer J.&#x20;Clinicians</source> <volume>65</volume>, <fpage>87</fpage>&#x2013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21262</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torre</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Global Cancer Incidence and Mortality Rates and Trends-An Update</article-title>. <source>Cancer Epidemiol. Biomarkers Prev.</source> <volume>25</volume>, <fpage>16</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-15-0578</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molecular Imaging in the Second Near&#x2010;Infrared Window</article-title>. <source>Adv. Funct. Mater.</source> <volume>29</volume>, <fpage>1900566</fpage>. <pub-id pub-id-type="doi">10.1002/adfm.201900566</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019a</year>). <article-title>Advanced Nanotechnology Leading the Way to Multimodal Imaging&#x2010;Guided Precision Surgical Therapy</article-title>. <source>Adv. Mater.</source> <volume>31</volume>, <fpage>1904329</fpage>. <pub-id pub-id-type="doi">10.1002/adma.201904329</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>NIR-II Nanoprobes <italic>In-Vivo</italic> Assembly to Improve Image-Guided Surgery for Metastatic Ovarian Cancer</article-title>. <source>Nat. Commun.</source> <volume>9</volume>, <fpage>2898</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-05113-8</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>Fabrication of Red Blood Cell-Based Multimodal Theranostic Probes for Second Near-Infrared Window Fluorescence Imaging-Guided Tumor Surgery and Photodynamic Therapy</article-title>. <source>Theranostics</source> <volume>9</volume>, <fpage>369</fpage>&#x2013;<lpage>380</lpage>. <pub-id pub-id-type="doi">10.7150/thno.29817</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>NIR&#x2010;II Fluorescent Self&#x2010;Assembled Peptide Nanochain for Ultrasensitive Detection of Peritoneal Metastasis</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>58</volume>, <fpage>11001</fpage>&#x2013;<lpage>11006</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201905643</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Exploiting Molecular Probes to Perform Near&#x2010;infrared Fluorescence&#x2010;guided Surgery</article-title>. <source>View</source> <volume>1</volume>, <fpage>20200068</fpage>. <pub-id pub-id-type="doi">10.1002/viw.20200068</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Liposome-based Probes for Molecular Imaging: from Basic Research to the Bedside</article-title>. <source>Nanoscale</source> <volume>11</volume>, <fpage>5822</fpage>&#x2013;<lpage>5838</lpage>. <pub-id pub-id-type="doi">10.1039/c9nr00207c</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Advances and Perspectives in Near&#x2010;infrared Fluorescent Organic Probes for Surgical Oncology</article-title>. <source>WIREs Nanomed Nanobiotechnol</source> <volume>12</volume>, <fpage>1635</fpage>. <pub-id pub-id-type="doi">10.1002/wnan.1635</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Recent Progress on Molecularly Near-Infrared Fluorescent Probes for Chemotherapy and Phototherapy</article-title>. <source>Coord. Chem. Rev.</source> <volume>427</volume>, <fpage>213556</fpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2020.213556</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shuhendler</surname>
<given-names>A. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Activatable NIR Fluorescence/MRI Bimodal Probes for <italic>In Vivo</italic> Imaging by Enzyme-Mediated Fluorogenic Reaction and Self-Assembly</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>141</volume>, <fpage>10331</fpage>&#x2013;<lpage>10341</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b03649</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>R. Q.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P. Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y. Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Surgical Navigation for Malignancies Guided by Near&#x2010;Infrared&#x2010;II Fluorescence Imaging</article-title>. <source>Small Methods</source> <volume>5</volume>, <fpage>2001066</fpage>. <pub-id pub-id-type="doi">10.1002/smtd.202001066</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A Near-Infrared Fluorogenic Probe with Fast Response for Detecting Sodium Dithionite in Living Cells</article-title>. <source>Spectrochimica Acta A: Mol. Biomol. Spectrosc.</source> <volume>245</volume>, <fpage>118887</fpage>. <pub-id pub-id-type="doi">10.1016/j.saa.2020.118887</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yun</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>S. J.&#x20;J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Light in Diagnosis, Therapy and Surgery</article-title>. <source>Nat. Biomed. Eng.</source> <volume>1</volume>, <fpage>8</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/s41551-016-0008</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A Bright NIR-II Fluorescent Probe for Breast Carcinoma Imaging and Image-Guided Surgery</article-title>. <source>Chem. Commun.</source> <volume>55</volume>, <fpage>14287</fpage>&#x2013;<lpage>14290</lpage>. <pub-id pub-id-type="doi">10.1039/c9cc07694h</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liew</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hemicyanine&#x2010;Based Near&#x2010;Infrared Activatable Probes for Imaging and Diagnosis of Diseases</article-title>. <source>Angew. Chem. Int. Ed.</source> <pub-id pub-id-type="doi">10.1002/anie.202107877</pub-id> </citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Activatable Nanocomposite Probe for Preoperative Location and Intraoperative Navigation for Orthotopic Hepatic Tumor Resection via MSOT and Aggregation-Induced Near-IR-I/II Fluorescence Imaging</article-title>. <source>Anal. Chem.</source> <volume>92</volume>, <fpage>9257</fpage>&#x2013;<lpage>9264</lpage>. <pub-id pub-id-type="doi">10.1021/acs.analchem.0c01596</pub-id> </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Tumor Microenvironment-Activated NIR-II Reagents for Tumor Imaging and Therapy</article-title>. <source>J.&#x20;Mater. Chem. B</source> <volume>8</volume>, <fpage>4738</fpage>&#x2013;<lpage>4747</lpage>. <pub-id pub-id-type="doi">10.1039/d0tb00030b</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Antaris</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Near&#x2010;Infrared&#x2010;II Molecular Dyes for Cancer Imaging and Surgery</article-title>. <source>Adv. Mater.</source> <volume>31</volume>, <fpage>1900321</fpage>. <pub-id pub-id-type="doi">10.1002/adma.201900321</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>